Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial

BACKGROUND: The STREAM trial demonstrated that a 9–11-month “short” regimen had non-inferior efficacy and comparable safety to a 20+ month “long” regimen for the treatment of rifampicin-resistant tuberculosis. Imbalance in the components of the composite primary outcome merited further investigation...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, P. P. J., Van Deun, A., Ahmed, S., Goodall, R. L., Meredith, S. K., Conradie, F., Chiang, C-Y, Rusen, I. D., Nunn, A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640464/
https://www.ncbi.nlm.nih.gov/pubmed/33143704
http://dx.doi.org/10.1186/s12916-020-01770-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640464/
https://www.ncbi.nlm.nih.gov/pubmed/33143704
http://dx.doi.org/10.1186/s12916-020-01770-z

Ejemplares similares